Spectral AI

Executive Summary

Spectral AI is a predictive analytics company leveraging multispectral imaging and proprietary AI algorithms to assess and predict wound healing. Its flagship product, the DeepView Wound Imaging System, provides clinicians with immediate, non-invasive diagnostic information to guide treatment decisions for acute and chronic wounds, particularly diabetic foot ulcers (DFUs). The company operates in the United States and the United Kingdom, targeting a large and growing market driven by the rising prevalence of diabetes and chronic wounds. Spectral AI's technology has the potential to reduce amputation rates and healthcare costs by enabling earlier and more precise interventions. Spectral AI is well-positioned for growth, with a clear regulatory pathway and strong clinical evidence supporting its platform. The company has secured strategic partnerships and is expanding its commercial footprint. Upcoming catalysts include potential expansion of FDA clearance, adoption by major healthcare systems, and publication of pivotal trial results. With a differentiated approach and supportive market trends, Spectral AI represents a compelling opportunity in the AI-driven diagnostics space.

Upcoming Catalysts (preview)

• Q3 2026Expanded FDA Clearance for New Indications60% success
• Q4 2026Landmark Partnership with a Major Hospital System70% success
• Q3 2026Publication of Pivotal Clinical Study Results80% success